Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.

Amino acid BCAA BTR CLD Cirrhosis

Journal

Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794

Informations de publication

Date de publication:
26 Mar 2024
Historique:
received: 18 12 2023
accepted: 28 02 2024
medline: 26 3 2024
pubmed: 26 3 2024
entrez: 26 3 2024
Statut: aheadofprint

Résumé

The branched-chain amino acids (BCAAs) to tyrosine (Tyr) ratio (BTR) test is used to evaluate the progression of chronic liver disease (CLD). However, the differences across sex, age, body mass index (BMI) and etiologies are still unclear. We retrospectively reviewed data from 2,529 CLD cases with free amino acids (FAAs) in peripheral blood from four hospitals and 16,421 general adults with FAAs data from a biobank database. In total, 1,326 patients with CLD (covering seven etiologies) and 8,086 healthy controls (HCs) were analyzed after exclusion criteria. We investigated the change of BTR in HCs by sex, age and BMI and then compared these to patients divided by modified ALBI (mALBI) grade after propensity score matching. BTR is significantly higher in males than females regardless of age or BMI and decreases with aging in HCs. In 20 types of FAAs, 7 FAAs including BCAAs were significantly decreased, and 11 FAAs including Tyr were significantly increased by mALBI grade in total CLD. The decreasing timings of BTR were at mALBI grade 2b in all CLD etiologies compared to HCs, however in chronic hepatitis C (CHC), chronic hepatitis B (CHB) and alcoholic liver disease (ALD), BTR started to decrease at 2a. There was a positive correlation between BCAAs and albumin among parameters in BTR and mALBI. The correlation coefficients in PBC, ALD and MASLD were higher than those of other etiologies. BTR varies by sex and age even among healthy adults, and decreasing process and timing of BTR during disease progression is different among CLD etiologies.

Sections du résumé

BACKGROUND BACKGROUND
The branched-chain amino acids (BCAAs) to tyrosine (Tyr) ratio (BTR) test is used to evaluate the progression of chronic liver disease (CLD). However, the differences across sex, age, body mass index (BMI) and etiologies are still unclear.
METHODS METHODS
We retrospectively reviewed data from 2,529 CLD cases with free amino acids (FAAs) in peripheral blood from four hospitals and 16,421 general adults with FAAs data from a biobank database. In total, 1,326 patients with CLD (covering seven etiologies) and 8,086 healthy controls (HCs) were analyzed after exclusion criteria. We investigated the change of BTR in HCs by sex, age and BMI and then compared these to patients divided by modified ALBI (mALBI) grade after propensity score matching.
RESULTS RESULTS
BTR is significantly higher in males than females regardless of age or BMI and decreases with aging in HCs. In 20 types of FAAs, 7 FAAs including BCAAs were significantly decreased, and 11 FAAs including Tyr were significantly increased by mALBI grade in total CLD. The decreasing timings of BTR were at mALBI grade 2b in all CLD etiologies compared to HCs, however in chronic hepatitis C (CHC), chronic hepatitis B (CHB) and alcoholic liver disease (ALD), BTR started to decrease at 2a. There was a positive correlation between BCAAs and albumin among parameters in BTR and mALBI. The correlation coefficients in PBC, ALD and MASLD were higher than those of other etiologies.
CONCLUSIONS CONCLUSIONS
BTR varies by sex and age even among healthy adults, and decreasing process and timing of BTR during disease progression is different among CLD etiologies.

Identifiants

DOI: 10.1007/s00535-024-02092-0 PMID: 38530472
pubmed: 38530472
doi: 10.1007/s00535-024-02092-0
pii: 10.1007/s00535-024-02092-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Japanese Society of Gastroenterology.

Références

Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1611–44.
doi: 10.1002/hep.32049 pubmed: 34233031
Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease. Gut. 1978;19:1068–73.
doi: 10.1136/gut.19.11.1068 pubmed: 730076 pmcid: 1412250
Häussinger D, Dhiman RK, Felipo V, et al. Hepatic encephalopathy. Nat Rev Dis Primers. 2022;8:43.
doi: 10.1038/s41572-022-00366-6 pubmed: 35739133
Tuo S, Yeo YH, Chang R, et al. Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. Clin Nutr. 2023;43:84–94.
doi: 10.1016/j.clnu.2023.11.008 pubmed: 38016243
Holman A, Parikh N, Clauw DJ, et al. Contemporary management of pain in cirrhosis: Toward precision therapy for pain. Hepatology. 2023;77:290–304.
doi: 10.1002/hep.32598 pubmed: 35665522
Caraceni P, O’Brien A, Gines P. Long-term albumin treatment in patients with cirrhosis and ascites. J Hepatol. 2022;76:1306–17.
doi: 10.1016/j.jhep.2022.03.005 pubmed: 35589252
Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.
doi: 10.1016/S1542-3565(05)00017-0 pubmed: 16206505
Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193–9.
doi: 10.1016/j.nut.2014.07.005 pubmed: 25441595
Hiraoka A, Michitaka K, Kiguchi D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29:1416–23.
doi: 10.1097/MEG.0000000000000986 pubmed: 29016470
Sano A, Tsuge S, Kakazu E, et al. Plasma free amino acids are associated with sarcopenia in the course of hepatocellular carcinoma recurrence. Nutrition. 2021;84:111007.
doi: 10.1016/j.nut.2020.111007 pubmed: 33745507
Kakazu E, Kondo Y, Kogure T, et al. Supplementation of branched-chain amino acids maintains the serum albumin level in the course of hepatocellular carcinoma recurrence. Tohoku J Exp Med. 2013;230:191–6.
doi: 10.1620/tjem.230.191 pubmed: 23892757
Konstantis G, Pourzitaki C, Chourdakis M, et al. Efficacy of branched chain amino acids supplementation in liver cirrhosis: A systematic review and meta-analysis. Clin Nutr. 2022;41:1171–90.
doi: 10.1016/j.clnu.2022.03.027 pubmed: 35500317
Fischer JE, Funovics JM, Aguirre A, et al. The role of plasma amino acids in hepatic encephalopathy. Surgery. 1975;78:276–90.
pubmed: 807982
Azuma Y, Maekawa M, Kuwabara Y, et al. Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. Clin Chem. 1989;35:1399–403.
doi: 10.1093/clinchem/35.7.1399 pubmed: 2758584
Yamamoto H, Kondo K, Tanaka T, et al. Reference intervals for plasma-free amino acid in a Japanese population. Ann Clin Biochem. 2016;53:357–64.
doi: 10.1177/0004563215583360 pubmed: 25829462
Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis-aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20:388–98.
doi: 10.1038/s41575-023-00759-2 pubmed: 36977794 pmcid: 10043867
Enomoto H, Ueno Y, Hiasa Y, et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2020;55:353–62.
doi: 10.1007/s00535-019-01645-y pubmed: 31768801
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56.
doi: 10.1016/j.jhep.2023.06.003 pubmed: 37364790
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98.
doi: 10.1038/nrendo.2017.151 pubmed: 29219149
GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 402:203–34
Sano A, Kakazu E, Morosawa T, et al. The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study. J Gastroenterol. 2018;53:978–88.
doi: 10.1007/s00535-018-1435-5 pubmed: 29380062
Gaggini M, Carli F, Rosso C, et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology. 2018;67:145–58.
doi: 10.1002/hep.29465 pubmed: 28802074
Brunt EM, Kleiner DE, Wilson LA, et al. NASH Clinical Research Network (CRN) nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD distinct clinicopathologic meanings. Hepatology. 2011;53:810–20.
doi: 10.1002/hep.24127 pubmed: 21319198
Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.
doi: 10.1002/hep.22906 pubmed: 19554543
Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.
doi: 10.1016/S0168-8278(99)80297-9 pubmed: 10580593
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.
doi: 10.1200/JCO.2014.57.9151 pubmed: 25512453
Hiraoka A, Kumada T, Tsuji K, et al. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer. 2019;8:121–9.
doi: 10.1159/000488778 pubmed: 31019902
Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4 an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.
doi: 10.1002/hep.21669 pubmed: 17567829
Terrlink T, van Leeuwen PA, Houdijk A. Plasma amino acids determined by liquid chromatography within 17 minutes. Clin Chem. 1994;40:245–9.
doi: 10.1093/clinchem/40.2.245 pubmed: 8313601
Koshiba S, Motoike I, Saigusa D, et al. Omics research project on prospective cohort studies from the Tohoku Medical Megabank Project. Genes Cells. 2018;23:406–17.
doi: 10.1111/gtc.12588 pubmed: 29701317
Rahimi MH, Shab-Bidar S, Mollahosseini M, et al. Branched-chain amino acid supplementation and exercise-induced muscle damage in exercise recovery: A meta-analysis of randomized clinical trials. Nutrition. 2017;42:30–6.
doi: 10.1016/j.nut.2017.05.005 pubmed: 28870476
Ghaibour K, Schuh M, Souali-Crespo S, et al. Androgen receptor coordinates muscle metabolic and contractile functions. J Cachexia Sarcopenia Muscle. 2023;14:1707–20.
doi: 10.1002/jcsm.13251 pubmed: 37208984 pmcid: 10401547
Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448–53.
doi: 10.1038/nm.2307 pubmed: 21423183 pmcid: 3126616
Jang C, Oh SF, Wada S, et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 2016;22:421–6.
doi: 10.1038/nm.4057 pubmed: 26950361 pmcid: 4949205
Blair MC, Neinast MD, Jang C, et al. Branched-chain amino acid catabolism in muscle affects systemic BCAA levels but not insulin resistance. Nat Metab. 2023;5:589–606.
doi: 10.1038/s42255-023-00794-y pubmed: 37100997
Holecek M. Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications. Nutrition. 2013;29:1186–91.
doi: 10.1016/j.nut.2013.01.022 pubmed: 23756281
Moriwaki H, Miwa Y, Tajika M, et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun. 2004;313:405–9.
doi: 10.1016/j.bbrc.2003.07.016 pubmed: 14684176

Auteurs

Masaaki Mino (M)

Department of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Akitoshi Sano (A)

Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan.

Eiji Kakazu (E)

Department of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan. kakazu@coral.ocn.ne.jp.
Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan. kakazu@coral.ocn.ne.jp.
Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan. kakazu@coral.ocn.ne.jp.

Hiroko Matsubara (H)

Department of Biobank, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo, Aobaku, Sendai, 980-0872, Japan.

Keisuke Kakisaka (K)

Division of Gastroenterology and Hepatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahabacho, Shiwagun, Iwate, Japan.

Takayuki Kogure (T)

Division of Gastroenterology, Tohoku Medical and Pharmaceutical University Miyagi, 1-15-1, Fukumuro, Miyaginoku, Sendai, 983-8536, Japan.

Katsunori Sekine (K)

Department of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Yoshihiko Aoki (Y)

Department of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Masatoshi Imamura (M)

Department of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Michitaka Matsuda (M)

Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Taiji Yamazoe (T)

Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Taizo Mori (T)

Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Sachiyo Yoshio (S)

Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Jun Inoue (J)

Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan.

Atsushi Masamune (A)

Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan.

Tatsuya Kanto (T)

Department of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.
Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Classifications MeSH